Brooks Laboratories is currently trading at Rs 16.80, up by 0.25 points or 1.51% from its previous closing of Rs. 16.55 on the BSE.
The scrip opened at Rs 16.80 and has touched a high and low of Rs. 16.80 and Rs 16.80 respectively.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 131.10 on 05-Sep-2011 and a 52 week low of Rs. 15.20 on 25-Nov-2011.
Last one week high and low of the scrip stood at Rs 17.30 and Rs 16.30 respectively. The current market cap of the company is Rs. 27.00 crore.
The promoters holding in the company stood at 60.77% while Non-Institutions hold 39.23% respectively.
Brooks Laboratories has received an approval for manufacture of Doripenem Monohydrate injection from Directorate General of Health Service. The company is all set to manufacture this drug within this fiscal year.
Doripenem is a broad spectrum anti-bacterial agent of carbapenem family. Growing bacterial resistance is major cause of concern for researchers as it contributors to increase in mortality, morbidity and treatment cost. Doripenem is an ultra broad spectrum anti bacterial agent of carbepenem family used to treat in complicated intra-abdominal infections and complicated urinary tract infections, including complicated and uncomplicated pylenephritis and cases with concurrent bacteremia.
Brooks Laboratories is into pharmaceutical contract research and manufacturing services. It is having wide range of products catering to critical care segment in Parental Section like Beta Lactam, Cephalosporin & General Dry powder Injectables, Ampoules and Liquid vials, Dry Syrups and Tablets etc.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1619.95 |
| Dr. Reddys Lab | 1315.85 |
| Cipla | 1294.75 |
| Zydus Lifesciences | 927.15 |
| Lupin | 2296.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: